Cisplatin

CAS No. 15663-27-1

Cisplatin( CDDP | cis-Diaminodichloroplatinum )

Catalog No. M12235 CAS No. 15663-27-1

A chemotherapy agent that interferes with DNA replication and kills cancer cells; induces growth arrest and/or apoptosis in most cancer cell types; an alkylating agent for treatment of a number of cancers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 25 In Stock
100MG 38 In Stock
500MG 87 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cisplatin
  • Note
    Research use only, not for human use.
  • Brief Description
    A chemotherapy agent that interferes with DNA replication and kills cancer cells; induces growth arrest and/or apoptosis in most cancer cell types; an alkylating agent for treatment of a number of cancers.
  • Description
    A chemotherapy agent that interferes with DNA replication and kills cancer cells; induces growth arrest and/or apoptosis in most cancer cell types; an alkylating agent for treatment of a number of cancers.Chemotherapeutic Agents Approved(In Vitro):Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK.Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively.(In Vivo):In melanoma-bearing mice, Cisplatin (CDDP; 4 mg/kg B.W.) reduces the size and weight of the solid tumors, and HemoHIM supplementation with Cisplatin enhances the decrease of both the tumor size and weight.Cisplatin administration results in significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and blood urea nitrogen by about 132, 315, 797, and 556% in comparison with the control rats, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CDDP | cis-Diaminodichloroplatinum
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA Alkylator
  • Recptor
    Caspase-3| Caspase-9
  • Research Area
    Cancer
  • Indication
    Chemotherapeutic

Chemical Information

  • CAS Number
    15663-27-1
  • Formula Weight
    300.051
  • Molecular Formula
    Cl2H6N2Pt
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 31 mg/mL (DMSO can inactivate Cisplatin's activity)
  • SMILES
    Cl[Pt-2]([NH3+])([NH3+])Cl
  • Chemical Name
    Platinum, diamminedichloro-, (SP-4-2)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wang X, et al. J Biol Chem. 2000 Dec 15;275(50):39435-43. 2. Cummings BS, et al. J Pharmacol Exp Ther. 2002 Jul;302(1):8-17. 3. Hall MD, et al. Cancer Res. 2014 Jul 15;74(14):3913-22.
molnova catalog
related products
  • Mitomycin C

    Mitomycin C (Ametycine) is a chemotherapeutic antibiotic that acts as a double-stranded DNA alkylating agent.

  • Alchemix

    A dual action as an alkylating agent and topoisomerase inhibitor with potent activity against anthracycline- and cisplatin-resistant tumor cancer.

  • Lomustine

    Lomustine is an Alkylating Drug. The mechanism of action of lomustine is as an Alkylating Activity.